FDA Approves Enbrel for Plaque Psoriasis

The U.S. Food and Drug Administration has approved the biologic drug Enbrel to treat chronic, moderate to severe plaque psoriasis in adults. The drug, marketed by Amgen and Wyeth Pharmaceuticals, is already approved to treat psoriatic arthritis.

Related Resources:

• The Facts of Enbrel
• Fast Facts About Psoriatic Arthritis
• Psoriatic Arthritis Screening Quiz
• Psoriatic Arthritis: Test Your Knowledge
• Primary Symptoms of Psoriatic Arthritis
• Psoriatic Arthritis and Rheumatoid Arthritis - What's the Difference?